In Vivo is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Can Big Pharma Save Biotech Investors?

Executive Summary

All the biotech stock indices are down; record numbers of companies are selling at lower-than-cash valuations. Investors want Pharma to step up and buy, removing inventory from the market, and spreading limited investment dollars over a smaller set of opportunities. While buyers say they aren't going to radically change their strategies simply to take advantage of cheap prices, it's clear that more deals will get signed - mostly because more sellers will accept terms they once would have rejected. . In short, a hotter dealmaking climate will keep biotech healthy enough to survive as an industry, albeit a smaller one, and, perhaps, with a slightly lower ceiling on returns.
Advertisement

Related Content

Dealmaking When Pharma's the Only Game in Town
Corporate Venture Takes Center Stage
Biopharma in 2008: What a Difference an Economic Crisis Makes
Biopharma in 2008: What a Difference an Economic Crisis Makes
Best of the Blog, START-UP, December 2008
The A-List: 2008's Trend Shaping Series A Financings
Reacting to the Crisis: Biotech Venture Capital's Plan B
Vitae's Debt Financing: Crucial Lifeline in a Tightening Financial Market
Genzyme: Why Diversification is Starting to Look Smart
Genzyme: Why Diversification is Starting to Look Smart

Topics

Related Companies

Related Deals

Advertisement
UsernamePublicRestriction

Register

IV003030

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel